AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer

QR Code

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer

Bibliographic Details
Main Authors:	Gianni, L., Romieu, G., Lichinister, M., Serrano, S., Mansutti, M., Pivot, X., Mariani, P., Andre, F., Chan, Arlene, Lipatov, O., Chan, S., Wardley, A., Greil, R., Moore, N., Prot, S., Pallaud, C., Semiglazov, V.
Format:	Journal Article
Published:	American Society of Clinical Oncology 2013
Online Access:	http://hdl.handle.net/20.500.11937/4315

Similar Items

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2013)

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2010)

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2010)

Trastuzumab biosimilar in early breast cancer setting: Will there be direct patient benefits?
by: Chan, Arlene
Published: (2017)

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
by: Chan, Arlene, et al.
Published: (2016)

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2013)

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab
by: Chan, Arlene, et al.
Published: (2012)

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
by: Cameron, David, et al.
Published: (2013)

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
by: De Boer, R., et al.
Published: (2012)

HER2 positive metastatic breast cancer: What happens after first line failure?
by: Chan, Arlene
Published: (2016)

Adjuvant trastuzumab in HER2-positive breast cancer.
by: Slamon, D., et al.
Published: (2011)

TILs in metastatic breast cancer—no surprises, but more questions
by: Chan, Arlene
Published: (2017)

Capecitabine and vinorelbine in metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2009)

Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study
by: Au, H., et al.
Published: (2013)

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study
by: Bergh, J., et al.
Published: (2012)

Prevalence of Excessive Tearing in Women With Early Breast Cancer Receiving Adjuvant Docetaxel-Based Chemotherapy
by: Chan, Arlene, et al.
Published: (2013)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan, Arlene, et al.
Published: (2012)

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2014)

Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
by: Chan, Arlene
Published: (2016)

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial
by: Eiermann, W., et al.
Published: (2011)

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
by: Chan, Arlene, et al.
Published: (2016)

Vomiting in docetaxel chemotherapy: which to blame, dose or gene?
by: Jabir, Rafid, et al.
Published: (2014)

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
by: Mackey, J., et al.
Published: (2016)

Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.]
by: Hasbullah, Harissa H, et al.
Published: (2018)

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
by: Martin, M., et al.
Published: (2017)

Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma
by: Grill, Jacques, et al.
Published: (2018)

An investigation of metastatic colorectal cancer
by: Asiri, Abutaleb
Published: (2018)

Biocompatible hyperbranched polyglycerol modified ß-cyclodextrin derivatives for docetaxel delivery
by: Xu, Z., et al.
Published: (2017)

Development and characterization of docetaxel and curcumin-loaded aerosolized nanoemulsion for pulmonary cancer
by: Asmawi, Azren Aida
Published: (2020)

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer
by: Cinieri, S., et al.
Published: (2017)

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase 11 study
by: Hyams, D., et al.
Published: (2013)

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
by: Baselga, J., et al.
Published: (2017)

Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability
by: Badran, Mohamed M., et al.
Published: (2018)

Development and validation of HPLC method for quantification of docetaxel in palm-based nanoemulsion aerosols
by: Asmawi, Azren Aida, et al.
Published: (2020)

Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial
by: Gianni, L., et al.
Published: (2018)

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
by: Dent, R., et al.
Published: (2013)

An investigation of metastatic markers in models of paediatric medulloblastoma
by: Nasir, Aishah
Published: (2017)

Investigating the role of Cten in metastatic colorectal cancer
by: Thorpe, Hannah
Published: (2016)

Metastatic adenocarcinoma of the lung mimicking spinal tuberculosis
by: Zakaria@Mohamad, Zamzuri, et al.
Published: (2011)

Multifunctional Poly(D,L-Lactide-co-Glycolide)/ Montmorillonite (PLGA/MMT) Nanoparticles Decorated by Trastuzumab for Targeted Chemotherapy of Breast Cancer
by: Ranganathan, Balu, et al.
Published: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qgdr17a49kfjrvgb06s2ehmm4f